KR102213617B1 - Cosmetic or pharmaceutical composition for skin whitening or anti-inflammation comprising pulchinenoside B4 - Google Patents

Abstract

The present invention provides a composition for skin whitening or anti-inflammatory, in particular a cosmetic composition, a pharmaceutical composition, and a health food comprising a compound represented by the following formula (1) as an active ingredient. The cosmetic or pharmaceutical composition of the present invention has few side effects, so it is safe for the human body and has excellent skin whitening and anti-inflammatory effects.
[Formula 1]

Description

A cosmetic or pharmaceutical composition for skin whitening or anti-inflammation comprising pulchinenoside B4}

The present invention relates to a cosmetic composition, a pharmaceutical composition, and a health food having an excellent effect such as skin whitening or anti-inflammatory, particularly having excellent effects related to the skin. The present invention also relates to a cosmetic composition, a pharmaceutical composition and a health food that can exert the above effect even in a small amount.

It is a common desire to have white and fair skin. The color or brightness of the skin is genetically determined according to the concentration and distribution of melanin in human skin, but is also affected by environmental or physiological conditions such as solar ultraviolet rays, fatigue or stress. Melanin is produced through a non-enzymatic oxidation reaction after being sequentially changed into dopa and dopaquinone by an enzyme called tyrosinase acting as a catalyst in tyrosine, a kind of amino acid. As such, the pathway by which melanin is produced is known, but the cause of the triggering of tyrosinase in the mechanism that induces melanin synthesis is still not elucidated in detail.

Meanwhile, as a commonly known whitening component, substances that inhibit tyrosinase enzyme activity such as Kojic acid or arbutin, hydroquinone, vitamin C (L-Ascorbic acid) or derivatives thereof, and various There are plant extracts. By inhibiting the synthesis of melanin pigments, they can not only realize skin whitening by brightening skin tone, but also improve skin hyperpigmentation such as spots and freckles caused by ultraviolet rays, hormones or genetics. However, when applied to the skin, there is a problem in that the amount of use is limited due to safety issues such as irritation and redness, or the effect is insignificant and thus no practical effect can be expected.

Glycation refers to a reaction in which simple sugars such as glucose or fructose form covalent bonds to proteins or fats that generally occur without the involvement of enzymes. Saccharification takes place through a series of complex chemical reactions known as Amadori reactions and Maiyar reactions, resulting in the formation of advanced glycation endproducts (AGEs).

On the other hand, the glycosylation process of protein occurs slowly because enzyme action is not involved, and as a result, proteins with long half-life, such as collagen, have more influence. As a result of analysis of the final glycated product, glycated collagen was accumulated with age, and the accumulation of the final glycated product changed the protein into a hard and brittle state, and glycated collagen in the extracellular matrix of the dermal layer. By preventing collagen from forming the proper structure, it loses the elasticity of the skin and promotes wrinkle formation (Dyer, DG et al, The Journal of Clinical Investigation., 9, p. 2463, 1993).

In addition, the final saccharification product produced by saccharification is known to accumulate on the dermal layer as skin aging progresses as a brownish substance. As skin aging progresses, it is thought to be the causative agent that gradually turns yellowish, and it is known that the reflected light reflected from the skin decreases as a specific final glycated product accumulates. While the amount of melanin pigment in the skin has a weak relationship with skin aging, the amount of the final glycated product accumulated in the dermal layer of the skin gradually increases as skin aging progresses and can make the face look dull (Hiroshi, O. et al, Skin). Research and Technology, 15, p. 496, 2009)

As substances that inhibit saccharification, aminoguanidine, pyridoxamine, and aspirin are known, but these substances have limited amounts of use due to safety issues on the skin, or their effects are insignificant. There is a problem that cannot be expected.

Inflammation is an immune response of the human body in response to wounds or diseases, and oxidative stress such as ultraviolet rays, free radicals, etc. activates inflammatory factors, causing various diseases and aging of the skin. Vasoactive polypeptides such as Kinin, Plasmin, or Complement act as vasodilation, contraction, and chemotaxis, and other lymphokines such as interleukin-6 (IL-6) Phosphorus and arachidonic acid are responsible for the inflammatory response. Arachidonic acid is metabolized to prostaglandin or Lukotriene, which are inflammatory mediators through two pathways, Cyclooxygenase or Lipooxygenase, mediating various inflammatory reactions.

On the other hand, in order to eliminate inflammation, it is called an anti-inflammatory agent that acts to remove inflammatory sources, reduce biological reactions, and symptoms. Substances used for anti-inflammatory purposes to date include flufenamic acid, ibuprofen, Benzydamine, or Indomethacin as non-steroids, and Prednisolone as a steroid system. Or dexamethasone. In addition, allantoin, azene, hydrocortisone, etc. are known to be effective in anti-inflammatory, but these substances are limited in use due to safety issues on the skin, or the effect is insignificant, so there is a problem that it is not possible to substantially alleviate inflammation. have.

Therefore, there is an urgent need for the development of ingredients that are safe for the living body, have stable active ingredients, and, above all, have skin whitening and anti-inflammatory effects that are superior to existing substances having skin whitening and anti-inflammatory effects.

Accordingly, the present invention solves the above problems, has few side effects, is safe for the human body, and provides a new active ingredient having excellent skin whitening or anti-inflammatory effect, that is, such a useful use of the active ingredient.

In other words, the problem to be solved by the present invention is to provide a composition comprising an active ingredient having excellent efficacy as an active ingredient.

In order to solve the above problems, the present invention is a composition for skin whitening or anti-inflammatory (improving skin troubles) comprising pulchinenoside B4 as an active ingredient, preferably a cosmetic composition, a pharmaceutical composition or a health food Provides.

That is, the present invention provides a new use of fulkinenoside B4 for skin whitening or anti-inflammatory.

The inventors of the present invention confirmed that fulkinenoside B4 exhibits an anti-glycosylation effect, suppresses NO production, has an anti-inflammatory effect, and suppresses melanin synthesis to exhibit a whitening effect, and completed the present invention.

In the present invention, "whitening effect" refers to not only brightening skin tone by inhibiting the synthesis of melanin pigment, but also improving skin hyperpigmentation such as spots and freckles caused by ultraviolet rays, hormones, or genetics.

In the present invention, the term'anti-inflammatory or inflammation improvement' refers to suppressing inflammation, and the inflammation is one of the defense responses of living tissues against a certain stimulus, and includes three types of tissue deterioration, circulation disorders and effusion, and tissue proliferation. It refers to a complex lesion that occurs together. More specifically, inflammation is part of innate immunity, and, as in other animals, innate immunity in humans recognizes patterns on the cell surface that are specific to pathogens. Phagocytes recognize cells with such surfaces as non-magnetic and attack pathogens. If pathogens break through the body's physical barriers, an inflammatory reaction occurs. The inflammatory reaction is a nonspecific defense action that creates a hostile environment for microorganisms invading the wound. In the inflammatory reaction, when a wound or an external infectious agent enters the body, white blood cells responsible for the early stage immune response gather and express cytokines. Therefore, the amount of expression of cytokines in cells becomes an indicator of activation of the inflammatory response. Examples of skin diseases related to inflammation include atopic dermatitis, psoriasis, erythematous disease triggered by radiation, chemicals, burns, etc., acid burns, bullous skin disease, lichen shape type disease, itching due to allergies, seborrheic eczema, rose acne, Pemphigus vulgaris, polymorphic exudative erythema, nodular erythema, balanitis, vulvitis, inflammatory hair loss such as alopecia areata, cutaneous T-cell lymphoma, and the like, but are not limited thereto. In particular, through the anti-inflammatory effect of the present invention, it is possible to improve skin troubles such as acne.

The present invention provides a composition comprising a compound represented by the following Formula 1 in order to solve the above problems and achieve the object of the present invention.

[Formula 1]

The compound represented by Formula 1 has a molecular formula of C ₅₉ H ₉₆ O ₂₆ and a molecular weight of 1221.38, and is named as pulchinenoside B4, Chinensioside A; Pulchinenoside C; Anemoside B4; Pulchinenoside B4; Pulsatilla saponin B4, and the like.

The present invention is not particularly limited to the method of obtaining the fulkinenoside B4, and chemically synthesized by a method known in the art, or a commercially available material may be used.

In the cosmetic composition, pharmaceutical composition and health food according to the present invention, the content of fulkinenoside B4 is preferably 0.00001 to 10% by weight based on the total weight of the cosmetic composition, pharmaceutical composition and health food.

The fulkinenoside B4 of the present invention may exist in a non-solvated form as well as a solvated form including a form such as a hydrate and an ethanolic product. The fulkinenoside B4 of the present invention may exist in a crystalline or amorphous form, and all such physical forms are included in the scope of the present invention.

The cosmetic composition for skin whitening and anti-inflammatory according to the present invention is a solution, external ointment, cream, foam, nutrient lotion, softening lotion, pack, softening water, emulsion, makeup base, essence, soap, liquid cleanser, bathing agent, sunscreen cream , Sun oil, suspension, emulsion, paste, gel, lotion, powder, soap, surfactant-containing cleansing, oil, powder foundation, emulsion foundation, wax foundation, patch and spray However, it is not limited thereto.

In addition, the cosmetic composition of the present invention may additionally include one or more cosmetically acceptable carriers blended in general skin cosmetics, and as common ingredients, for example, oil, water, surfactant, moisturizer, lower alcohol, A thickener, a chelating agent, a colorant, a preservative, a fragrance, and the like may be appropriately mixed, but the present invention is not limited thereto.

The cosmetically acceptable carrier included in the cosmetic composition of the present invention varies depending on the formulation. When the formulation of the present invention is an ointment, paste, cream or gel, animal oil, vegetable oil, wax, paraffin, starch, tracant, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc, zinc oxide or Mixtures of these can be used.

When the formulation of the present invention is a powder or spray, lactose, talc, silica, aluminum hydroxide, calcium silicate, polyamide powder, or mixtures thereof may be used as a carrier component, and in particular, in the case of a spray, additional chloro Propellants such as fluorohydrocarbon, propane/butane or dimethyl ether.

When the formulation of the present invention is a solution or emulsion, a solvent, a solubilizing agent, or an emulsifying agent is used as a carrier component, such as water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl benzoate, propylene glycol, 1,3 -Butylglycol oil, in particular cottonseed oil, peanut oil, corn germ oil, olive oil, castor oil and sesame oil, glycerol aliphatic ester, polyethylene glycol or fatty acid ester of sorbitan.

When the formulation of the present invention is a suspension, as a carrier component, a liquid diluent such as water, ethanol or propylene glycol, an ethoxylated isostearyl alcohol, a suspending agent such as polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, micro Crystalline cellulose, aluminum metahydroxide, bentonite, agar or tracant, and the like may be used.

When the formulation of the present invention is a soap, an alkali metal salt of a fatty acid, a fatty acid hemiester salt, a fatty acid protein hydrolyzate, isethionate, a lanolin derivative, an aliphatic alcohol, vegetable oil, glycerol, sugar, etc. may be used as a carrier component. I can.

The present invention also provides a skin whitening and anti-inflammatory method comprising the step of applying the compound represented by Formula 1 to the skin of an individual. The subject includes, without limitation, mammals including mice, livestock, humans, and the like.

According to another embodiment of the present invention, the present invention provides a pharmaceutical composition for skin whitening or anti-inflammatory containing the compound of Formula 1 as an active ingredient.

The composition comprising the compound of the present invention may be in various oral or parenteral formulations, but preferably may be a parenteral formulation. In the case of formulation, it is prepared using diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrants, and surfactants that are usually used. Solid preparations for oral administration include tablets, pills, powders, granules, capsules, and the like, and these solid preparations include at least one excipient in one or more compounds, such as starch, calcium carbonate, sucrose, or lactose ( lactose), gelatin, etc. In addition, in addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Liquid preparations for oral administration include suspensions, liquid solutions, emulsions, and syrups.In addition to water and liquid paraffin, which are commonly used simple diluents, various excipients such as humectants, sweeteners, fragrances, and preservatives may be included. have. Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, and emulsions. As the non-aqueous solvent and suspension, propylene glycol, polyethylene glycol, vegetable oil such as olive oil, and injectable ester such as ethyl oleate may be used.

The present invention can also be provided as a formulation of an external preparation for skin for skin whitening and anti-inflammatory effects comprising the compound of Formula 1 as an active ingredient.

When the compound of Formula 1 is used for external skin, additionally fatty substances, organic solvents, solubilizers, thickening and gelling agents, emollients, antioxidants, suspending agents, stabilizers, foaming agents, fragrances, surfactants , Water, ionic or nonionic emulsifiers, fillers, sequestering agents and chelating agents, preservatives, vitamins, blockers, wetting agents, essential oils, dyes, pigments, hydrophilic or lipophilic actives, lipid vesicles or external preparations for skin It may contain adjuvants commonly used in the field of dermatology, such as any other ingredients used as. In addition, the above ingredients may be introduced in amounts generally used in the field of dermatology.

When the compound of Formula 1 is provided in a formulation for external application for skin, it is not limited thereto, but may have a formulation such as an ointment, patch, gel, cream, or spray.

The pharmaceutical composition of the present invention may be particularly preferably used as a parenteral preparation. For example, the external preparation for skin may include a suitable pharmaceutically acceptable base such as petrolatum and stearyl alcohol; Suitable pharmaceutically acceptable surfactants such as polysorbate and sorbitan sesquioleate; Pharmaceutically acceptable suitable moisturizers such as glycerin; Suitable pharmaceutically acceptable solvents; And a flavoring agent, a colorant, a stabilizer, a viscous agent, and the like are homogeneously mixed.

In addition, when the compound of Formula 1 of the present invention is used as a medicine, it may further contain one or more active ingredients exhibiting the same or similar function. For example, known skin whitening and anti-inflammatory ingredients may be included. When the additional skin whitening and anti-inflammatory components are included, the skin whitening and anti-inflammatory effects of the composition of the present invention may be further enhanced. When the above ingredients are added, skin safety, ease of formulation, and stability of active ingredients can be considered in combination with use. In one embodiment of the present invention, the composition is an anti-inflammatory component known in the art, including a COX-2 inhibitor, prednisolone and allantoin; As whitening ingredients known in the art, substances that inhibit tyrosinase enzyme activity such as Kojic acid, arbutin, etc., hydroquinone, vitamin-C (L-Ascorbic acid); and derivatives thereof And it may further include one or more components selected from the group consisting of various plant extracts. Additional ingredients may be included in an amount of 0.0001% to 10% by weight based on the total weight of the composition, and the content range may be adjusted according to requirements such as skin safety and ease of formulation of the compound of Formula 1 .

When the pharmaceutical composition of the present invention contains an effective amount of the compound of Formula 1, it can provide a desirable skin whitening effect and an anti-inflammatory effect. In the present invention, the term "effective amount" means an amount of a compound capable of exhibiting a skin whitening effect, an elasticity enhancement and wrinkle improvement effect, or a moisturizing effect.

The effective amount of the compound of Formula 1 included in the composition of the present invention will vary depending on the form in which the composition is commercialized, the method in which the compound is applied to the skin, and the time it stays on the skin. For example, when the composition is commercialized as a pharmaceutical, it may contain the compound of Formula 1 at a higher concentration than when it is commercialized as a cosmetic that is routinely applied to the skin. Therefore, the daily dosage is 0.1 to 100 mg/kg, preferably 30 to 80 mg/kg, more preferably 50 to 60 mg/kg, based on the amount of the compound of Formula 1, and 1 to It can be administered 6 times.

According to another embodiment of the present invention, a health food containing the compound of Formula 1 is provided for skin whitening and anti-inflammatory effects.

In the present specification, the term'health food' refers to food prepared by adding the compound of Formula 1 to food materials such as beverages, teas, spices, gums, confectionery, or encapsulating, powdering, suspension, etc. It means bringing a specific effect, but unlike general drugs, it has the advantage of not having side effects that may occur when taking drugs for a long time using food as a raw material. Since the health food of the present invention obtained in this way can be consumed on a daily basis, high skin whitening effect, elasticity enhancing effect, wrinkle improvement effect, and moisturizing effect can be expected, and thus it is very useful.

When the compound of Formula 1 is used as a food additive, the compound of Formula 1 may be added as it is or may be used together with other foods or food ingredients, and may be appropriately used according to a conventional method. The mixed amount of the active ingredient may be appropriately determined according to the purpose of use (prevention, health or therapeutic treatment). In general, in the preparation of food or beverage, the composition of the present invention is added in an amount of 15 parts by weight or less, preferably 10 parts by weight or less based on the raw material. However, in the case of long-term intake for the purpose of health and hygiene or for the purpose of health control, the amount may be less than the above range, and there is no problem in terms of safety, so the active ingredient may be used in an amount above the above range. . There is no particular limitation on the type of food. Examples of foods to which the above substances can be added include meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gum, dairy products including ice cream, various soups, beverages, tea, drinks, There are alcoholic beverages and vitamin complexes, and it includes all health foods in the usual sense. The health beverage composition of the present invention may contain various flavoring agents or natural carbohydrates as an additional component, like a conventional beverage. The natural carbohydrates described above are monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, and polysaccharides such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol and erythritol. As the sweetener, natural sweeteners such as taumatin and stevia extract, and synthetic sweeteners such as saccharin and aspartame can be used. The proportion of the natural carbohydrate is generally about 0.01 to 0.04 g, preferably about 0.02 to 0.03 g per 100 mL of the composition of the present invention. In addition to the above, the health food of the present invention includes various nutrients, vitamins, electrolytes, flavoring agents, colorants, pectic acids and salts thereof, alginic acid and salts thereof, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols. , Carbonated beverages used in carbonated beverages, and the like. In addition, the health food of the present invention may contain pulp for the manufacture of natural fruit juice, fruit juice beverage and vegetable beverage. These ingredients may be used independently or in combination. The ratio of these additives is not very important, but it is generally selected from 0.01 to 0.1 parts by weight per 100 parts by weight of the composition of the present invention.

Although not limited thereto, in one embodiment of the present invention, the composition may include 0.00001% to 10% by weight of the compound of Formula 1 based on the total weight of the composition.

The composition containing fulkinenoside B4 of the present invention exhibits a skin whitening effect.

The composition containing fulkinenoside B4 of the present invention exhibits an anti-inflammatory effect or an effect of improving skin problems.

The composition containing fulkinenoside B4 of the present invention can be used as a safe and excellent cosmetic raw material and pharmaceutical ingredient.

Hereinafter, in order to describe the present invention in more detail, it will be described with reference to the following examples. However, the embodiments according to the present invention may be modified into various other forms, and the scope of the present invention should not be construed as being limited to the embodiments described below. Embodiments of the present invention are provided by way of example to aid in a specific understanding of the present invention.

Reference example One: Full Kineno Seed B4( Pulchinenoside B4) substance information

[Formula 1]

Name of substance: Pulchinenoside B4

CAS No. : 129741-57-7

Molecular Formula: C ₅₉ H ₉₆ O ₂₆

Molecular Weight: 1221.38

Where to buy: Tauto Biotech (China)

Example 1: anti-inflammatory effect- NO Production inhibitory effect

In order to confirm the anti-inflammatory effect and skin trouble alleviation effect of the compound of Formula 1, a Nitric oxide (NO) formation inhibition test was performed by the GRIESS method using RAW264.7 cell line (ATCC number: CRL-2278).

Specifically, RAW264.7 cells, which are mouse macrophages, were subcultured several times, placed in a 24-well plate so as to enter 3×10 ⁵ cells in each well, and cultured for 24 hours. Then, it was replaced with a cell medium diluted with the compound of Formula 1 at a final concentration of 1, 10, and 100 ppm. At this time, the NO-production inhibitor L-NMMA (L-NG-Monomethylarginine) was treated together as a positive control and incubated for 30 minutes, and 1 μg of LPS (Lipopolysaccharide) was treated as a stimulator and cultured for 24 hours. . 100 μl of the supernatant is taken and transferred to a 96-well plate, 100 μl of the GRIESS solution is added to react at room temperature for 10 minutes, and the absorbance at 540 nm is measured to determine the NO inhibitory effect of the compound of Formula 1, and the result It is shown in Table 1 below.

NO production inhibitory effect of the substance of formula 1

sample NO production inhibition rate (%) Control (DMSO, 10ppm) - L-NMMA (positive control, 10ppm) 41.02 Compound of Formula 1 (1ppm) 10.73 Compound of Formula 1 (10ppm) 17.11 Compound of Formula 1 (100ppm) 25.63

As can be seen from the results of Table 1, when compared to the representative anti-inflammatory drug L-NMMA, the compound of Formula 1 has low activity, but it can be confirmed that it exhibits excellent activity as a natural substance.

Not only can it be used alone in pharmaceutical or cosmetic compositions for anti-inflammatory or skin trouble improvement, but also in whitening, wrinkle improvement, or skin trouble improvement, anti-inflammatory effect acts as an auxiliary role, so synergistic effect can be expected.

Example 2: whitening effect-reducing the total amount of melanin

The whitening effect was confirmed by measuring the total amount of melanin at the cell level by adding the compound of Formula 1 to the culture medium of mouse melanoma cells (B-16 mouse melanoma cells) (Lotan R., Lotan D. Cancer) Res . 40:3345-3350, 1980). Before the experiment, toxicity was evaluated for the melanoma cells of mice, and a non-toxic concentration was selected to perform whitening evaluation.

The final concentration of the compound of Formula 1 was 1 ppm and 10 ppm in the culture solution, and arbutin, a control, was added to the medium so as to be 100 ppm, and each treated with B-16 melanoma cells was cultured for 3 days.

Thereafter, the cells were treated with trypsin, removed from the culture vessel, centrifuged, and melanin was extracted. The detached cells were boiled for 10 minutes by adding 1 ml of sodium hydroxide solution (1N concentration) to dissolve melanin, and the absorbance was measured at 400 nm using a spectrophotometer to measure the amount of melanin produced.

The amount of melanin was measured by a method expressed by absorbance per unit cell count (1×10 ⁶ cells), and the total amount of melanin relative to the control was calculated as an inhibition rate (%), and the results are summarized in Table 4.

The effect of reducing the total amount of melanin at the cellular level according to the concentration

sample Melanin production
(abs) Inhibition rate (%) Control (DMSO, 10ppm) 0.33 - Positive control (Arbutin, 100ppm) 0.228 31.06 Formula 1 (10ppm) 0.214 35.04 Formula 1 (1ppm) 0.263 20.37

As can be seen from the results of Table 2, when compared to arbutin, which is known as a whitening material, the compound of Formula 1 exhibits better melanin production inhibition even when a smaller concentration is applied to the melanoma cells of the cultured mouse. , It was confirmed that the total amount of melanin was less.

Therefore, it was found that the compound of Formula 1 can be used for whitening purposes.

Example 3: Anti-glycosylation effect

In order to confirm the anti-glycation effect, the glycosylation inhibitory activity was measured using L-arginine and glucose.

First, prepare by dissolving 1M L-arginine and 1M glucose using 1M phosphate buffer solution (pH 7.4), and dilute the sample to 50 or 100 ppm using 1M phosphate buffer solution. Mix 1M L-azinine and 1M phosphate buffer in a ratio of 1 to 4, and then dispense 80 μl into a 96-well plate. Add 100 μl of each sample diluted to 50 and 100 ppm and 0.01M aminoguanidin to be used as a positive control. After mixing these samples well, add glucose diluted with 1M phosphate buffer so that the final concentration of glucose becomes 0.1M. It was reacted for 4 hours at 70 ℃. The degree of saccharification was measured on a 96-well plate by measuring absorbance at 420 nm using a spectrophotometer.

The Glycation experiment group of the following formula is an experimental group in which 1M L-azinine and 1M glucose are added to induce saccharification.In order to measure the absorbance of the sample itself, 1M L-Aginine and only the sample are added without glucose to measure the absorbance at 420 nm. I did. The glycosylation inhibitory activity can be calculated as follows.

Anti-glycosylation effect of the compound of formula 1

sample Inhibition rate (%) Control (DMSO, 50ppm) - Positive control (Aminoguanidine, 55ppm) 54.89 Compound of Formula 1 (50ppm) 37.95 Compound of Formula 1 (25ppm) 20.65

As can be seen from the results of Table 3, it is believed that the compound of Formula 1 exhibits an excellent anti-glycosylation effect and thus can have a whitening effect.

Claims (4)

A cosmetic composition for skin whitening comprising a compound represented by the following Formula 1 as an active ingredient.
[Formula 1]

A health food composition for skin whitening comprising a compound represented by the following Formula 1 as an active ingredient.
[Formula 1]

The cosmetic composition of claim 1, wherein the compound represented by Formula 1 is contained in an amount of 0.00001 to 10% by weight based on the total weight of the cosmetic composition. The health food composition of claim 2, wherein the compound represented by Formula 1 is contained in an amount of 0.00001 to 10% by weight based on the total weight of the health food composition.